On September 15, Arrowhead Pharmaceuticals fell 8.95% in regular trading, trading at $73.45/share, with turnover of $125 million. The decline was triggered by the company's release of interim topline clinical data for its first dual-function RNAi therapy targeting mixed hyperlipidemia.

Specifically, Arrowhead disclosed that its single ascending dose study has advanced to the 400mg dose level with no drug-related serious adverse events reported, indicating a favorable safety and tolerability profile. However, the announcement referenced only \"preliminary efficacy signals,\" with notably conservative language that fell short of investor expectations regarding the strength of efficacy data. The cautious wording appeared to fuel doubts about the therapy's clinical potency, prompting profit-taking pressure.

The data release comes amid a broader period of pipeline momentum for Arrowhead, including the European Commission's marketing authorization for Redemplo (Plozasiran) for familial chylomicronemia syndrome granted in June, a licensing deal with Madrigal Pharmaceuticals worth up to $975 million in milestones, and multiple analyst upgrades with price targets ranging from $87 to $100. Despite this backdrop, the market reacted negatively to the perceived lack of robust efficacy evidence in the latest interim readout.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)